Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Omalizumab alfa injection

Omashu® is approved for the treatment of moderate to severe persistent allergic asthma in patients aged 15 years and above whose symptoms cannot be effectively controlled after treatment with inhaled corticosteroids and long-acting β2-receptor agonists, providing a new treatment option for many allergic asthma patients.



Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.